Serum cytokine inflammatory profile in children with ulcerative colitis during 6-month follow-up Authors: Katarzyna Zdanowicz, Mateusz Maciejczyk, Jacek Jamiołkowski, Dariusz Marek Lebensztejn, Urszula Daniluk Published: 2025 ABSTRACT The involvement of inflammation in the development of ulcerative colitis (UC) is significant. Therefore, the purpose of our study was to evaluate the serum levels of selected cytokines, chemokines and growth factors in children at the time of diagnosis/exacerbation of UC (T0), as well as 3 (T1) and 6 (T2) months after the introduction or change of treatment, and to assess their usefulness in predicting the course of the disease and the need for treatment intensification. Thirty-three children (study group) with UC, including 25 with new diagnoses of UC (ndUC), and 29 healthy controls (Ctr) were included in the study. Serum cytokine panels were measured at three time points: T0, T1, and T2 using multiplex ELISA method. At T0, significantly higher levels of IL-8, IL-17, eotaxin, and granulocyte colony-stimulating factor (G-CSF) were observed in both the UC and ndUC groups. At T1, higher levels of IL-17, eotaxin, and fibroblast growth factor (FGF) were noted in the study group compared to controls. When the group was stratified according to clinical activity at 6 months, IL-17, eotaxin, and FGF levels at T0 were higher in patients who achieved Pediatric Ulcerative Colitis Activity Index (PUCAI) < 10 compared to those with PUCAI ≥ 10. However, these associations should be interpreted with caution due to the heterogeneity of treatment interventions, which likely influenced the outcomes. Our exploratory analyses indicate that serum cytokines may reflect disease activity and may help in understanding clinical outcomes in pediatric UC, although prospective studies with standardized treatment protocols are needed to confirm their predictive value.Supplementary InformationThe online version contains supplementary material available at 10.1038/s41598-025-33271-5. Introduction Inflammatory bowel disease (IBD) is a chronic, heterogeneous disease mainly affecting the gastrointestinal tract, which requires long-term monitoring and treatment. One subtype of inflammatory bowel disease is ulcerative colitis (UC)1. The pathogenesis of UC remains unclear; however, genetic, inflammatory, and environmental factors are believed to play a role1,2. UC in children compared to adults is characterized by more extensive disease, including pancolitis, and the need for more frequent use of systemic steroids, immunomodulators and biological treatment. Despite the use of drug regimen according to the guidelines, treatment failures are observed with both conventional and biologic therapies3,4. Therefore, more and more attention is being paid to an individualized approach to the treatment of patients with IBD5. Research on markers that will enable the selection of the most effective treatment with the lowest risk of side effects at the time of diagnosis or disease exacerbation is essential for appropriate care of patients with IBD. A promising approach to successfully treating UC may be to target the cause of the disease. One postulated factor in the development of UC is an impaired immune response and abnormalities in the network of cytokines, chemokines and growth factors (hereafter “cytokines”)6. Abnormalities in pro-inflammatory and anti-inflammatory molecules are observed in patients with IBD. A loss of balance between pro- and anti-inflammatory cytokines has been shown to influence the persistence of inflammation, leading to disease persistence with subsequent tissue destruction7–9. Moreover, genetic studies of one of the cytokines interleukin (IL)-10 and its receptors (IL10RA and IL10RB) have identified a distinct group of IBD patients, among whom very early-onset-IBD symptoms have been observed, as well as failure of standard immunosuppressive treatment10. The important role of cytokines in IBD may also be indicated by the use of infliximab and adalimumab, antibodies directed against one of the cytokines, tumor necrosis factor-α (TNFα). However, the high failure rate of anti-TNFα treatment indicates that other inflammatory mechanisms are also involved in IBD11. Data on long-term evaluation of cytokines in children with IBD are lacking. To date, several studies have been published in children with IBD, in which changes in single molecules were observed under the influence of treatment12,13. It should be noted that the treatment used in the aforementioned studies was not first-line treatment (vedolizumab)12 or was a comparison of the effect of standard treatment with experimental treatment (mesalamine vs. mesalamine in combination with UDCA)13. To the best of our knowledge, no studies have been published to date on changes in serum cytokine levels in patients with UC after standard treatment, and their usefulness in predicting the course of the disease. Therefore, the purpose of our study was to evaluate the serum levels of selected cytokines in children at the time of diagnosis/exacerbation of UC, as well as 3 and 6 months after the introduction/change of treatment. The second objective was to evaluate the usefulness of cytokines in predicting the course of UC and the need for intensification of treatment. Results Characteristics of study group Thirty-three children with UC (study group) were included in the study, and among them twenty five were newly diagnosed (ndUC group). Eight patients (24.24%) were included in the study group at the time of disease exacerbation. Twenty nine children constituted the control group (Ctr). Demographic and clinical characteristics of the included patients are shown in Table 1. A similar percentage of patients was noted in each subgroup of disease activity according to the Pediatric Ulcerative Colitis Activity Index (PUCAI) score. Pancolitis (E4) was the most frequently observed disease extent (36.36%) according to the Paris classification. Additionally, 54.5% of patients presented with severe endoscopic lesions as assessed by the Mayo score. Table 1Clinical characteristics of children with UC and Ctr at the T0.ParametersUC (n = 33)Ctr (n = 29) p Male n (%)13 (39.39%)16 (55.17%)NSAge median (range)14 (7–17)15 (7–17)NSBMI (pc)53 (4–97)58 (3–99)NS PUCAI median (range) Mild n (%)10 (30.30%)NA-Moderate n (%)13 (39.39%)NA-Severe n (%)10 (30.30%)NA- Mayo endoscopic score n (%) 0 n (%)0 (0.0%)NA-1 n (%)2 (6.06%)NA-2 n (%)13 (39.39%)NA-3 n (%)18 (54.55%)NA- Paris classification n (%) E1 n (%)6 (18.18%)NA-E2 n (%)9 (27.27%)NA-E3 n (%)6 (18.18%)NA-E4 n (%)12 (36.36%)NA- Treatment Naïve n (%)25 (75.76%)NA-5-ASA n (%)6 (18.18%)NA-5-ASA + AZA/6-MP n (%)2 (6.06%)NAUC-ulcerative colitis, Ctr-control group, PUCAI-Pediatric activity index, mild 10–34, moderate 35–64, severe > 65, Mayo endoscopic score, 0—normal colonic mucosa, 1—erythema, decreased vascular pattern, mild friability, 2—marked erythema, erosions, no vascular pattern, friability, 3—ulceration, spontaneous bleeding; Paris classification, E1—proctitis, E2—distal to splenic flexure colitis; E3—extensive colitis, distal to hepatic flexure, E4—pancolitis; 5-ASA-5-aminosalicylic acid; AZA-azathioprine; 6-MP- 6-mercaptopurine; NS—not significant; NA—not applicable. Table 1Clinical characteristics of children with UC and Ctr at the T0.ParametersUC (n = 33)Ctr (n = 29) p Male n (%)13 (39.39%)16 (55.17%)NSAge median (range)14 (7–17)15 (7–17)NSBMI (pc)53 (4–97)58 (3–99)NS PUCAI median (range) Mild n (%)10 (30.30%)NA-Moderate n (%)13 (39.39%)NA-Severe n (%)10 (30.30%)NA- Mayo endoscopic score n (%) 0 n (%)0 (0.0%)NA-1 n (%)2 (6.06%)NA-2 n (%)13 (39.39%)NA-3 n (%)18 (54.55%)NA- Paris classification n (%) E1 n (%)6 (18.18%)NA-E2 n (%)9 (27.27%)NA-E3 n (%)6 (18.18%)NA-E4 n (%)12 (36.36%)NA- Treatment Naïve n (%)25 (75.76%)NA-5-ASA n (%)6 (18.18%)NA-5-ASA + AZA/6-MP n (%)2 (6.06%)NAUC-ulcerative colitis, Ctr-control group, PUCAI-Pediatric activity index, mild 10–34, moderate 35–64, severe > 65, Mayo endoscopic score, 0—normal colonic mucosa, 1—erythema, decreased vascular pattern, mild friability, 2—marked erythema, erosions, no vascular pattern, friability, 3—ulceration, spontaneous bleeding; Paris classification, E1—proctitis, E2—distal to splenic flexure colitis; E3—extensive colitis, distal to hepatic flexure, E4—pancolitis; 5-ASA-5-aminosalicylic acid; AZA-azathioprine; 6-MP- 6-mercaptopurine; NS—not significant; NA—not applicable. Clinical characteristics of children with UC and Ctr at the T0. UC-ulcerative colitis, Ctr-control group, PUCAI-Pediatric activity index, mild 10–34, moderate 35–64, severe > 65, Mayo endoscopic score, 0—normal colonic mucosa, 1—erythema, decreased vascular pattern, mild friability, 2—marked erythema, erosions, no vascular pattern, friability, 3—ulceration, spontaneous bleeding; Paris classification, E1—proctitis, E2—distal to splenic flexure colitis; E3—extensive colitis, distal to hepatic flexure, E4—pancolitis; 5-ASA-5-aminosalicylic acid; AZA-azathioprine; 6-MP- 6-mercaptopurine; NS—not significant; NA—not applicable. Assessment of serum inflammatory profile at baseline (T0) Cytokines that were detected in less than 85% of patients, i.e., with concentrations below the limit of detection, were excluded from further analysis. The study analyzed the following cytokines: IL-4, IL-6, IL-7, IL-8, IL-9, IL-10, IL-13, IL-17, TNF-α, interferon γ (IFN-γ), interferon gamma-induced protein 10 (IP-10), monocyte chemoattractant protein-1 (MCP-1), macrophage inflammatory protein 1 α (MIP-1α), macrophage inflammatory protein 1 β (MIP-1β), eotaxin, regulated on activation, normal T cell expressed and secreted (RANTES), granulocyte colony stimulating factor (G-CSF), vascular endothelial growth factor (VEGF), fibroblast growth factor (FGF) and platelet-derived growth factor (PDGF). At the beginning of the study (T0) we observed significantly higher levels of IL-8, IL-17, eotaxin and G-CSF in the study group, as well as in the ndUC group compared to Ctr (Table 2). Analyzing the correlations between cytokine levels and PUCAI, we obtained a significant result for PUCAI and IL-8 (R = 0.47, p = 0.006), IL-17 (R = 0.38, p = 0.03), and IFNγ (R = 0.36, p = 0.04). In ndUC group the only correlation between PUCAI and IL-8 (R = 0.47, p = 0.02) was noted. No correlation was found between fecal calprotectin (fCal) and cytokines. In contrast, IP-10 levels correlated negatively with Mayo score (r =-0.36, p = 0.04). Patients at T0 were additionally divided according to PUCAI score into mild, moderate, and severe disease groups, and cytokine concentrations (IL-8, IL-17, eotaxin, and G-CSF), which significantly differentiated the study group from controls, were compared between these subgroups. Only IL-8 and IL-17 levels differed significantly depending on disease severity. The median IL-8 concentrations were 17.43 pg/mL in the mild group, 19.18 pg/mL in the moderate group, and 31.75 pg/mL in the severe group (p = 0.002). For IL-17, the corresponding median values were 7.98 pg/mL, 10.36 pg/mL, and 15.97 pg/mL, respectively (p = 0.03). Eotaxin and G-CSF levels did not differ significantly between PUCAI subgroups. Patients in different disease severity groups received various treatments after blood sampling for cytokine analysis. Those in the mild group were mainly treated with 5-ASA monotherapy (n = 8/10, 80%), while 6 out of 13 patients (46%) in the moderate group and 9 out of 10 patients (90%) in the severe group received systemic corticosteroids. The use of systemic steroids may have influenced the reduction of cytokine concentrations, particularly in patients with moderate and severe disease. Although differences in cytokine levels likely reflect disease activity, the potential effect of systemic steroid treatment on lowering cytokine concentrations should be taken into account when interpreting these results. Changes of serum inflammatory profile levels after 3 months (T1) and 6 months (T2) At T1 the significantly higher levels of fCal, IL-17, eotaxin and FGF were noted in the study group compared to Ctr, while at T2 only fCal significantly differentiated those groups (Table 2). Similar results at T1 and T2 were obtained in the ndUC group (Table 2) with the exception for FGF. Table 2Cytokines’ concentrations (median, min-max) assessed at T0, T1 and T2 in the study group (UC), NdUC group and the control group (Ctr). All values are presented as medians with minimum and maximum values. The statistical difference was analyzed by the Mann–Whitney U test.UC at T0 (n = 33)UC at T1 (n = 33)UC at T2 (n = 33)Ctr (n = 29)fCal(µg/g)2523 (100–3975)**296 (20-3697)**230 (20-3568)**37 (20–99)PUCAI50 (10–80)10 (0–80)5 (0–50)-IL-8 (pg/mL)22.20 (1.77–86.15)**10.88 (0.98-100.44)10.73 (1.64–94.40)9.82 (3.01-142.21)IL-17 (pg/mL)12.47 (2.67–29.59)**7.44 (1.83–30.43)**6.86 (2.67–25.59)5.05 (1.00-11.42)Eotaxin (pg/mL)161.14 (58.30-409.73)**162.23 (65.42-499.65)**128.14 (60.48-340.95)104.73 (39.57-238.55)FGF (pg/mL)29.92 (19.19–60.92)32.35 (21.36-123.24)*29.45 (14.47–53.03)28.98 (14.47–69.33)G-CSF (pg/mL)77.98 (28.68-166.26)*53.83 (16.85-220.02)55.39 (18.76–231.00)55.39 (19.56-197.93)ndUC at T0 (n = 25)ndUC at T1 (n = 25)ndUC at T2 (n = 25)Ctr (n = 29)fCal(µg/g)2523 (100–3975)**192 (20-2397)**163 (20-3568)**37 (20–99)PUCAI45 (10–75)5 (0–80)0 (0–50)-IL-8 (pg/mL)20.20 (1.77–86.15)**10.88 (0.98-100.44)10.01 (1.64–94.40)9.82 (3.01-142.21)IL-17 (pg/mL)14.42 (3.51–29.59)**7.18 (1.83–30.43)*6.86 (2.67–25.59)5.05 (1.00-11.42)Eotaxin (pg/mL)161.02 (58.30-409.73)**154.59 (65.42-499.65)**117.80 (60.48-340.95)104.73 (39.57-238.55)G-CSF (pg/mL)70.98 (28.68-166.26)*49.42 (18.76-220.02)56.99 (18.76–231.0)55.39 (19.56-197.93)UC-ulcerative colitis, ndUC – newly diagnosed ulcerative colitis, Ctr-control group IL-interleukin, FGF- fibroblast growth factor, G-CSF-granulocyte colony stimulating factor, T0 - baseline time, T1 - after 3 months, T2 - after 6 months; *p < 0.05; vs. Ctr, **p < 0.01; vs. Ctr, Table 2Cytokines’ concentrations (median, min-max) assessed at T0, T1 and T2 in the study group (UC), NdUC group and the control group (Ctr). All values are presented as medians with minimum and maximum values. The statistical difference was analyzed by the Mann–Whitney U test.UC at T0 (n = 33)UC at T1 (n = 33)UC at T2 (n = 33)Ctr (n = 29)fCal(µg/g)2523 (100–3975)**296 (20-3697)**230 (20-3568)**37 (20–99)PUCAI50 (10–80)10 (0–80)5 (0–50)-IL-8 (pg/mL)22.20 (1.77–86.15)**10.88 (0.98-100.44)10.73 (1.64–94.40)9.82 (3.01-142.21)IL-17 (pg/mL)12.47 (2.67–29.59)**7.44 (1.83–30.43)**6.86 (2.67–25.59)5.05 (1.00-11.42)Eotaxin (pg/mL)161.14 (58.30-409.73)**162.23 (65.42-499.65)**128.14 (60.48-340.95)104.73 (39.57-238.55)FGF (pg/mL)29.92 (19.19–60.92)32.35 (21.36-123.24)*29.45 (14.47–53.03)28.98 (14.47–69.33)G-CSF (pg/mL)77.98 (28.68-166.26)*53.83 (16.85-220.02)55.39 (18.76–231.00)55.39 (19.56-197.93)ndUC at T0 (n = 25)ndUC at T1 (n = 25)ndUC at T2 (n = 25)Ctr (n = 29)fCal(µg/g)2523 (100–3975)**192 (20-2397)**163 (20-3568)**37 (20–99)PUCAI45 (10–75)5 (0–80)0 (0–50)-IL-8 (pg/mL)20.20 (1.77–86.15)**10.88 (0.98-100.44)10.01 (1.64–94.40)9.82 (3.01-142.21)IL-17 (pg/mL)14.42 (3.51–29.59)**7.18 (1.83–30.43)*6.86 (2.67–25.59)5.05 (1.00-11.42)Eotaxin (pg/mL)161.02 (58.30-409.73)**154.59 (65.42-499.65)**117.80 (60.48-340.95)104.73 (39.57-238.55)G-CSF (pg/mL)70.98 (28.68-166.26)*49.42 (18.76-220.02)56.99 (18.76–231.0)55.39 (19.56-197.93)UC-ulcerative colitis, ndUC – newly diagnosed ulcerative colitis, Ctr-control group IL-interleukin, FGF- fibroblast growth factor, G-CSF-granulocyte colony stimulating factor, T0 - baseline time, T1 - after 3 months, T2 - after 6 months; *p < 0.05; vs. Ctr, **p < 0.01; vs. Ctr, Cytokines’ concentrations (median, min-max) assessed at T0, T1 and T2 in the study group (UC), NdUC group and the control group (Ctr). All values are presented as medians with minimum and maximum values. The statistical difference was analyzed by the Mann–Whitney U test. fCal (µg/g) fCal (µg/g) UC-ulcerative colitis, ndUC – newly diagnosed ulcerative colitis, Ctr-control group IL-interleukin, FGF- fibroblast growth factor, G-CSF-granulocyte colony stimulating factor, T0 - baseline time, T1 - after 3 months, T2 - after 6 months; *p < 0.05; vs. Ctr, **p < 0.01; vs. Ctr, At T1, in the study group, we noted the significant correlations between fCal and cytokines: IL-4 (R = 0.37, p = 0.04), IL-8 (R = 0.53, p = 0.002), IL-17 (R = 0.42, p = 0.02), eotaxin (R = 0.46, p = 0.01), FGF (R = 0.41, p = 0.03), G-CSF (R = 0.52, p = 0.003), TNFα (R = 0.37, p = 0.04), VEGF (R = 0.50, p = 0.01). No correlation between PUCAI and cytokines was found. At T1 in ndUC, the following correlations were observed between fCal and IL-8 (R = 0.66, p < 0.005), IL-17 (R = 0.51, p = 0.01), eotaxin (R = 0.53, p = 0.01), FGF (R = 0.47, p = 0.02), and G-CSF (R = 0.52, p = 0.01). And PUCAI correlated with FGF (R = 0.54, p = 0.005), G-CSF (R = 0.62, p = 0.001), MIP-1 α (R = 0.41, p = 0.04), and MIP-1b (R = 0.50, p = 0.01). At T2, in UC, we observed the significant correlations between fCal and IL-8 (R = 0.44, p = 0.02), FGF (R = 0.62, p < 0.001) and G-CSF (R = 0.58, p = 0.001), and between PUCAI and IL-7 (R=-0.66, p = 0.002). The similar results were obtained for the ndUC group i.e. the correlation between fCal and IL-8 (R = 0.53, p = 0.01), FGF (R = 0.60, p = 0.004), G-CSF (R = 0.62, p = 0.003), and the correlation between PUCAI and IL-7 (R=-0. 74, p = 0.003). Analyzing changes in cytokine concentrations during the six-month follow-up, we noted significant changes regarding IL-8, IL-17, MIP-1 α, MIP-1β as well as fCal and PUCAI in both the whole study group and ndUC group (Table 1a suppl., Fig. 1A). In addition, there was a significant change in FGF and RANTES concentrations in the study group, and VEGF concentrations in the ndUC group (Fig. 1B). Fig. 1A and B. Changes in cytokine concentrations (y-axis) during the six-month follow-up (x-axis) were observed in both the study group and the ndUC patients Cytokine levels are shown as a ratio to controls. Analysis was performed with the Friedman test with post hock analysis. A and B. Changes in cytokine concentrations (y-axis) during the six-month follow-up (x-axis) were observed in both the study group and the ndUC patients Cytokine levels are shown as a ratio to controls. Analysis was performed with the Friedman test with post hock analysis. Evaluation of cytokines based on PUCAI score at T2 In the next stage of the study, patients were divided according to PUCAI (≥ 10 points as active disease vs. < 10 points as clinical remission) assessed at T2, i.e. after 6 months of therapy (Table 3). At T2, 60.61% of children (n = 20) achieved clinical remission and only this group showed a significant decrease in fCal, IL-8, IL-17, MIP-1 α, and VEGF. Moreover, in the group with active disease after 6 months, the only cytokine that significantly changed its level during study period was RANTES (p = 0.02, in post hoc analysis, a decrease was observed between the levles determined at T0 and T1 with increase in T2) (Table 3). The levels of all tested cytokines in relation to PUCAI have been shown in Table 2 suppl. What is more, IL-17, eotaxin, FGF and MIP1a levels were higher at T0 in the group with PUCAI < 10 compared to the PUCAI ≥ 10 group assessed in 6 month. At T1 no differences in cytokine levels were observed between groups (data are not shown). For cytokines that showed significant differences at T0, we checked how many patients had higher cytokine levels than the control group in relation to disease activity assessed at T2. We found that 90.48% of patients with clinical remission at T2 showed higher eotaxin levels at baseline (T0) than controls, compared to only 50% of children with PUCAI ≥ 10 (p = 0.009). A similar pattern was observed for FGF (90.45% of patients with PUCAI < 10 at T2 vs. 33.33% of patients with PUCAI ≥ 10 at T2, p < 0.001) and IL-17 (95% of patients with PUCAI < 10 at T2 vs. 50% of children with PUCAI > 10, p = 0.03). For MIP-1 α, when comparing the number of patients with levels above the median from the control group, no significant differences were found between the two patient groups (31.25% and 25.00%, p = 0.94). Detailed information on the treatment of patients according to the achievement of clinical remission is provided in Table 3 suppl. During the follow-up period, significant changes in treatment regimens were observed at multiple time points, reflecting individualized adjustments based on disease activity. A substantial proportion of patients received steroids at some point during the study (ranging from 57.14 to 66.67% across different outcome groups), highlighting the impact of anti-inflammatory therapy on clinical and biochemical outcomes. These variations in treatment intensity, including the initiation of immunomodulators and biologics, likely influenced the observed cytokine dynamics, emphasizing that the results should be interpreted as reflective of both disease activity and therapeutic interventions. Table 3Changes in marker levels according to clinical disease activity assessed by PUCAI levels at T2. All values are presented as medians with minimum and maximum values. Comparisons within the same groups at T0, T1 and T2 were assessed using the Friedman test with post hoc analysis or cochran’s Q test with mcnemar’s test. Comparisons between groups at T0 were assessed using the Mann-Whitney U test .Parameters (n, %); (median; range)PUCAI < 10 at T2 (n = 21; 63.64%)PUCAI ≥ 10 at T2 (n = 12; 36.36%)UC T0UC T1UC T2P# T0 vs. T1 vs. T2UC T0UC T1UC T2P# T0 vs. T1 vs. T2p## T0 (PUCAI < 10) vs. T0 (PUCAI ≥ 10)Naive(n, %)18 (85.71%)0(0.0%)0(0.0%)NA7(58.33%)0(0.0%)0(0.0%)NA0.085-ASA (n, %)2 (9.52%)16 (76.19%)12 (57.14%)< 0.001(*, **)4 (33.33%)7 (58.33%)5 (41.67%)0.500.215-ASA + IMs +/-steroids(n, %)1 (4.76%)3 (14.29%)2 (9.52%)0.611 (8.33%)4 (33.33%)5 (41.67%)0.110.21Anti-TNF (n, %)0 (0.0%)2 (9.52%)7 (33.33%)NA0 (0.0%)1 (8.33%)2 (16.67%)NANAfCal(ug/g)2510 (358–3975)216(20-3656)163(20-3520)0.004 (*, **)2678(100–3203)1818 (20-3697)868(34-3568)0.500.87PUCAI45 (10–75)5 (0–80)0 (0–5)< 0.001 (*, **, ***)55 (10–80)15 (0–45)15 (10–50)0.002 (*, **)0.90IL-8(pg/mL)23.22 (2.21–86.15)11.94(1.64-100.44)8.72(1.64–31.83)0.02(*, ***)17.98(1.77–32.44)10.34 (0.98–63.78)12.69(4.19–94.40)0.640.08IL-17 (pg/mL)15.26 (4.34–29.59)7.18 (3.09–30.43)6.86 (2.67–16.95)0.03 (**)6.49(2.67–16.68)8.24 (1.83–15.63)5.18(0.24–25.59)0.130.004Eotaxin (pg/mL)185.51 (58.30-409.73)163.19 (65.42-499.65)113.17 (67.58-209.93)0.19144.76 (66.70-201.19)158.64 (79.4-187.95)132.81 (60.48-340.95)0.530.002FGF(pg/mL)29.92 (21.36–60.92)29.92 (21.36–61.10)28.98 (14.47–53.03)0.3024.15 (19.19–51.81)32.35 (21.36–51.81)29.92 (14.47–36.08)0.050.01MIP-1 α (pg/mL)2.54 (1.03–8.58)2.09 (0.80–5.23)1.67 (0.78–4.41)< 0.001 (*, **)1.65 (1.03–5.82)1.71 (0.78–2.64)2.43 (0.80–4.35)0.850.02RANTES (pg/mL)5535.48 (3835.01-29281.43)4953.06 (3417.11-11205.08)4997.23 (3882.93-12371.28)0.406077.86 (4267.86-16585.80)5330.51 (3567.25-12020.1)6551.95 (3113.43-12240.75)0.02 (*)0.40VEGF (pg/mL)182.38 (66.34-372.48)126.74 (22.89-368.87)150.96 (33.76–450.30)0.04 (*)150.96 (66.34-247.28)116.14 (22.89-436.49)118.30 (98.85–207.80)0.780.16T0 - baseline time, T1 - after 3 months, T2 - after 6 months, PUCAI-Pediatric activity index, fCal-fecal calprotectin, CRP—C-reactive protein, ESR—erythrocyte sedimentation rate, IL-interleukin, FGF- fibroblast growth factor, MIP-1 α- macrophage inflammatory protein 1 α, RANTES- regulated on activation, normal T cell expressed and secreted, VEGF- vascular endothelial growth factor.*p < 0.05 for T0 vs. T1, **p < 0.05 for T0 vs. T2, ***p < 0.05 for T1 vs. T2, determined using the Friedman test with post hoc analysis; # results obtained using the Friedman test/Cochran’s Q test with McNemar’s test,## results obtained using the Mann-Whitney U test. Table 3Changes in marker levels according to clinical disease activity assessed by PUCAI levels at T2. All values are presented as medians with minimum and maximum values. Comparisons within the same groups at T0, T1 and T2 were assessed using the Friedman test with post hoc analysis or cochran’s Q test with mcnemar’s test. Comparisons between groups at T0 were assessed using the Mann-Whitney U test .Parameters (n, %); (median; range)PUCAI < 10 at T2 (n = 21; 63.64%)PUCAI ≥ 10 at T2 (n = 12; 36.36%)UC T0UC T1UC T2P# T0 vs. T1 vs. T2UC T0UC T1UC T2P# T0 vs. T1 vs. T2p## T0 (PUCAI < 10) vs. T0 (PUCAI ≥ 10)Naive(n, %)18 (85.71%)0(0.0%)0(0.0%)NA7(58.33%)0(0.0%)0(0.0%)NA0.085-ASA (n, %)2 (9.52%)16 (76.19%)12 (57.14%)< 0.001(*, **)4 (33.33%)7 (58.33%)5 (41.67%)0.500.215-ASA + IMs +/-steroids(n, %)1 (4.76%)3 (14.29%)2 (9.52%)0.611 (8.33%)4 (33.33%)5 (41.67%)0.110.21Anti-TNF (n, %)0 (0.0%)2 (9.52%)7 (33.33%)NA0 (0.0%)1 (8.33%)2 (16.67%)NANAfCal(ug/g)2510 (358–3975)216(20-3656)163(20-3520)0.004 (*, **)2678(100–3203)1818 (20-3697)868(34-3568)0.500.87PUCAI45 (10–75)5 (0–80)0 (0–5)< 0.001 (*, **, ***)55 (10–80)15 (0–45)15 (10–50)0.002 (*, **)0.90IL-8(pg/mL)23.22 (2.21–86.15)11.94(1.64-100.44)8.72(1.64–31.83)0.02(*, ***)17.98(1.77–32.44)10.34 (0.98–63.78)12.69(4.19–94.40)0.640.08IL-17 (pg/mL)15.26 (4.34–29.59)7.18 (3.09–30.43)6.86 (2.67–16.95)0.03 (**)6.49(2.67–16.68)8.24 (1.83–15.63)5.18(0.24–25.59)0.130.004Eotaxin (pg/mL)185.51 (58.30-409.73)163.19 (65.42-499.65)113.17 (67.58-209.93)0.19144.76 (66.70-201.19)158.64 (79.4-187.95)132.81 (60.48-340.95)0.530.002FGF(pg/mL)29.92 (21.36–60.92)29.92 (21.36–61.10)28.98 (14.47–53.03)0.3024.15 (19.19–51.81)32.35 (21.36–51.81)29.92 (14.47–36.08)0.050.01MIP-1 α (pg/mL)2.54 (1.03–8.58)2.09 (0.80–5.23)1.67 (0.78–4.41)< 0.001 (*, **)1.65 (1.03–5.82)1.71 (0.78–2.64)2.43 (0.80–4.35)0.850.02RANTES (pg/mL)5535.48 (3835.01-29281.43)4953.06 (3417.11-11205.08)4997.23 (3882.93-12371.28)0.406077.86 (4267.86-16585.80)5330.51 (3567.25-12020.1)6551.95 (3113.43-12240.75)0.02 (*)0.40VEGF (pg/mL)182.38 (66.34-372.48)126.74 (22.89-368.87)150.96 (33.76–450.30)0.04 (*)150.96 (66.34-247.28)116.14 (22.89-436.49)118.30 (98.85–207.80)0.780.16T0 - baseline time, T1 - after 3 months, T2 - after 6 months, PUCAI-Pediatric activity index, fCal-fecal calprotectin, CRP—C-reactive protein, ESR—erythrocyte sedimentation rate, IL-interleukin, FGF- fibroblast growth factor, MIP-1 α- macrophage inflammatory protein 1 α, RANTES- regulated on activation, normal T cell expressed and secreted, VEGF- vascular endothelial growth factor.*p < 0.05 for T0 vs. T1, **p < 0.05 for T0 vs. T2, ***p < 0.05 for T1 vs. T2, determined using the Friedman test with post hoc analysis; # results obtained using the Friedman test/Cochran’s Q test with McNemar’s test,## results obtained using the Mann-Whitney U test. Changes in marker levels according to clinical disease activity assessed by PUCAI levels at T2. All values are presented as medians with minimum and maximum values. Comparisons within the same groups at T0, T1 and T2 were assessed using the Friedman test with post hoc analysis or cochran’s Q test with mcnemar’s test. Comparisons between groups at T0 were assessed using the Mann-Whitney U test . Naive (n, %) 0 (0.0%) 0 (0.0%) 7 (58.33%) 0 (0.0%) 0 (0.0%) fCal (ug/g) 216 (20-3656) 163 (20-3520) 2678 (100–3203) 868 (34-3568) IL-8 (pg/mL) 11.94 (1.64-100.44) 8.72 (1.64–31.83) 0.02 (*, ***) 17.98 (1.77–32.44) 12.69 (4.19–94.40) 6.49 (2.67–16.68) 5.18 (0.24–25.59) FGF (pg/mL) T0 - baseline time, T1 - after 3 months, T2 - after 6 months, PUCAI-Pediatric activity index, fCal-fecal calprotectin, CRP—C-reactive protein, ESR—erythrocyte sedimentation rate, IL-interleukin, FGF- fibroblast growth factor, MIP-1 α- macrophage inflammatory protein 1 α, RANTES- regulated on activation, normal T cell expressed and secreted, VEGF- vascular endothelial growth factor. *p < 0.05 for T0 vs. T1, **p < 0.05 for T0 vs. T2, ***p < 0.05 for T1 vs. T2, determined using the Friedman test with post hoc analysis; # results obtained using the Friedman test/Cochran’s Q test with McNemar’s test, ## results obtained using the Mann-Whitney U test. ROC analysis To evaluate the ability of the markers assessed at T0 (baseline) to predict clinical remission (PUCAI < 10) at T2, we performed ROC analysis (Table 4). The best results for AUC (> 0.8) were obtained for eotaxin (with 66.7% sensitivity and 91.7% specificity at the cut-off level 166.28 pg/mL). Table 4Analysis of diagnostic efficiency of selected markers evaluated at T0 that significantly differentiated patients with and without clinical remission in T2.ParameterAUCSE95% C.I.(AUC) p Cut-offSensitivitySpecificityIL-17 T00.8120.0750.664–0.959< 0.00114.42 pg/mL66.7%91.7%Eotaxin T00.8170.0760.668–0.967< 0.001166.28 pg/mL66.7%91.7%FGF T00.7660.0910.558–0.9430.00326.57 pg/mL81.0%66.7%MIP-1 α T00.7400.0980.548–0.9320.011.96 pg/mL85.7%66.7%AUC-area under the curve, C.I,-confidence interval, SE-standard error, ESR—erythrocyte sedimentation rate, IL-interleukin, FGF- fibroblast growth factor, MIP-1 α- macrophage inflammatory protein 1 α, T0- baseline time. Table 4Analysis of diagnostic efficiency of selected markers evaluated at T0 that significantly differentiated patients with and without clinical remission in T2.ParameterAUCSE95% C.I.(AUC) p Cut-offSensitivitySpecificityIL-17 T00.8120.0750.664–0.959< 0.00114.42 pg/mL66.7%91.7%Eotaxin T00.8170.0760.668–0.967< 0.001166.28 pg/mL66.7%91.7%FGF T00.7660.0910.558–0.9430.00326.57 pg/mL81.0%66.7%MIP-1 α T00.7400.0980.548–0.9320.011.96 pg/mL85.7%66.7%AUC-area under the curve, C.I,-confidence interval, SE-standard error, ESR—erythrocyte sedimentation rate, IL-interleukin, FGF- fibroblast growth factor, MIP-1 α- macrophage inflammatory protein 1 α, T0- baseline time. Analysis of diagnostic efficiency of selected markers evaluated at T0 that significantly differentiated patients with and without clinical remission in T2. AUC-area under the curve, C.I,-confidence interval, SE-standard error, ESR—erythrocyte sedimentation rate, IL-interleukin, FGF- fibroblast growth factor, MIP-1 α- macrophage inflammatory protein 1 α, T0- baseline time. Univariate and multivariate analysis Univariate regression model analysis revealed only three cytokines (IL-17, eotaxin, FGF) that were significantly associated with achieving clinical remission at 6 months (Table 5). An odds ratio > 1 was obtained for the baseline variables, suggesting that higher initial levels of these parameters may be positively associated with the likelihood of achieving clinical remission after six months. Next, for the multivariate analysis, the 2 variables with the lowest p-values (IL-17 (T0) and eotaxin (T0) were selected (Table 5). Although the model showed a relatively high AUC of 0.853, the variables used did not reach statistical significance. Table 5Univariate and multivariate analyses yielding significant predictors of achieving clinical remission assessed 6 months after diagnosis/exacerbation of UC.VariableOdds ratio (95% C.I.) p Univariate IL-17 T01.26 (1.06–1.50)0.008Eotaxin T01.02 (1.01–1.04)0.01FGF T01.11 (1.01–1.24)0.04 Multivariate IL-17 T01.160 (0.973–1.382)0.10Eotaxin T01.016 (0.995–1.037)0.15C.I.-confidence interval, IL-interleukin, FGF- fibroblast growth factor, ESR-erythrocyte sedimentation rate, T0 - baseline time. Table 5Univariate and multivariate analyses yielding significant predictors of achieving clinical remission assessed 6 months after diagnosis/exacerbation of UC.VariableOdds ratio (95% C.I.) p Univariate IL-17 T01.26 (1.06–1.50)0.008Eotaxin T01.02 (1.01–1.04)0.01FGF T01.11 (1.01–1.24)0.04 Multivariate IL-17 T01.160 (0.973–1.382)0.10Eotaxin T01.016 (0.995–1.037)0.15C.I.-confidence interval, IL-interleukin, FGF- fibroblast growth factor, ESR-erythrocyte sedimentation rate, T0 - baseline time. Univariate and multivariate analyses yielding significant predictors of achieving clinical remission assessed 6 months after diagnosis/exacerbation of UC. C.I.-confidence interval, IL-interleukin, FGF- fibroblast growth factor, ESR-erythrocyte sedimentation rate, T0 - baseline time. Evaluation of cytokines based on fCal levels at T2 In the next phase of the study, patients were stratified based on fCal levels measured at T2, using a cut-off of < 250 µg/g to indicate fCal-defined remission and > 250 µg/g to indicate failure to achieve fCal-defined remission (Table 6). Detailed information on the treatment of patients according to the achievement of fCal-defined remission is provided in Table 3 suppl. Interestingly, there were no differences in cytokine levels at T0 between these groups. However, both groups, with low fCal (< 250 µg/g) or high fCal (> 250 µg/g) at T2, achieved a significant decrease in PUCAI (between T0 and T1 as well as between T0 and T2). Only in the group that achieved fCal-defined remission there was a significant decrease in IL-4, IL-8, IL-17, eotaxin, FGF and MIP-1 α during the study period (Table 6). Table 2 suppl. presents the levels of all tested cytokines in relation to fCal. Due to the lack of significant differences in cytokine concentrations at T0 between the two groups, ROC analysis and regression analysis were not performed. Table 6Changes in marker levels according to achieved fCal-defined remission assessed by fCal levels at T2. All values are presented as medians with minimum and maximum values. Comparisons within the same groups at T0, T1 and T2 were assessed using the Friedman test with post hoc analysis or cochran’s Q test with mcnemar’s test. Comparisons between groups at T0 were assessed using the Mann-Whitney U test .Parameters (median; range)fCal < 250 µg/g in T2 (n = 17; 51.52%)fCal > 250 µg/g in T2 (n = 16; 48.48%)T0T1T2P# T0 vs. T1 vs. T2T0T1T2P# T0 vs. T1 vs. T2P## T0 (fCal < 250 ug/g) vs. T0 (fCal > 250 ug/g)ndUC (n, %)14 (82.35%)0 (0.0%)0 (0.0%)NA11 (68.75%)0 (0.0%)0 (0.0%)NA0.365-ASA (n, %)3 (17.65%)13 (76.47%)12 (70.59%)0.002 (*)3 (18.75%)10 (62.50%)5 (31.25%)0.050.945-ASA + IMs + steroids (n, %)0 (0.0%)2 (11.76%)1 (5.88%)NA2 (12.50%)5 (31.25%)6 (37.5%)0.28NAAnti-TNF (n, %)0 (0.0%)2 (11.76%)4 (23.53%)NA0 (0.0%)1 (6.25%)5 (31.25%)NANAPUCAI40 (10–8010 (0–65)10 (0–65)< 0.001 (*, **)55 (10–75)10 (0–80)10 (0–80)0.001 (*, **)0.53IL-4 (pg/mL)6.39 (1.77–17.68)7.20 (0.39–15.34)5.84 (2.02–10.97)0.03 (**)5.84 (3.48–12.83)5.84 (2.7-12.58)4.97 (2.26-16,17)0.420.59IL-8 (pg/mL)20.20 (7.93–86.15)10.72 (0.98-100.44)8.72 (1.64–15.09)0.002 (**)24.69 (1.77–65.07)12.47 (1.77–80.03)14.22 (4.19–94.40)0.090.66IL-17 (pg/mL)14.42 (2.67–29.59)7.97 (1.83–19.47)6.60 (2.67–8.24)< 0.001 (**)11.95 (4.34–24.02)7.13 (3.51–30.43)6.86 (3.51–25.59)0.230.68Eotaxin (pg/mL)172.86 (58.30-409.73)162.23 (65.42-499.65)117.80 (68.78-209.93)0.002 (**)155.46 (66.70-278.65)159.12 (79.40-277.24)153.34 (60.48-340.95)0.940.51FGF (pg/mL)29.92 (19.19–60.92)29.92 (21.36–61.10)25.35 (14.47–41.38)0.02 (**)29.92 (19.19–51.81)34.22 (25.35–46.91)32.35 (21.36–53.03)0.670.98MIP-1 α (pg/mL)2.62 (1.03–8.58)2.16 (0.78–5.23)1.62 (1.03–2.94)0.006 (**)1.89 (1.22–5.58)1.82 (0.91–3.60)1.80 (0.78–4.41)0.050.10T0 - baseline time, T1 - after 3 months, T2 - after 6 months, PUCAI-Pediatric activity index, fCal-fecal calprotectin,, IL-interleukin, FGF- fibroblast growth factor, MIP-1 α- macrophage inflammatory protein 1a.*p < 0.05 for T0 vs. T1, **p < 0.05 for T0 vs. T2, ***p < 0.05 for T1 vs. T2, determined using the Friedman test with post hoc analysis; # results obtained using the Friedman test/Cochran’s Q test with McNemar’s test.## results obtained using the Mann-Whitney U test. Table 6Changes in marker levels according to achieved fCal-defined remission assessed by fCal levels at T2. All values are presented as medians with minimum and maximum values. Comparisons within the same groups at T0, T1 and T2 were assessed using the Friedman test with post hoc analysis or cochran’s Q test with mcnemar’s test. Comparisons between groups at T0 were assessed using the Mann-Whitney U test .Parameters (median; range)fCal < 250 µg/g in T2 (n = 17; 51.52%)fCal > 250 µg/g in T2 (n = 16; 48.48%)T0T1T2P# T0 vs. T1 vs. T2T0T1T2P# T0 vs. T1 vs. T2P## T0 (fCal < 250 ug/g) vs. T0 (fCal > 250 ug/g)ndUC (n, %)14 (82.35%)0 (0.0%)0 (0.0%)NA11 (68.75%)0 (0.0%)0 (0.0%)NA0.365-ASA (n, %)3 (17.65%)13 (76.47%)12 (70.59%)0.002 (*)3 (18.75%)10 (62.50%)5 (31.25%)0.050.945-ASA + IMs + steroids (n, %)0 (0.0%)2 (11.76%)1 (5.88%)NA2 (12.50%)5 (31.25%)6 (37.5%)0.28NAAnti-TNF (n, %)0 (0.0%)2 (11.76%)4 (23.53%)NA0 (0.0%)1 (6.25%)5 (31.25%)NANAPUCAI40 (10–8010 (0–65)10 (0–65)< 0.001 (*, **)55 (10–75)10 (0–80)10 (0–80)0.001 (*, **)0.53IL-4 (pg/mL)6.39 (1.77–17.68)7.20 (0.39–15.34)5.84 (2.02–10.97)0.03 (**)5.84 (3.48–12.83)5.84 (2.7-12.58)4.97 (2.26-16,17)0.420.59IL-8 (pg/mL)20.20 (7.93–86.15)10.72 (0.98-100.44)8.72 (1.64–15.09)0.002 (**)24.69 (1.77–65.07)12.47 (1.77–80.03)14.22 (4.19–94.40)0.090.66IL-17 (pg/mL)14.42 (2.67–29.59)7.97 (1.83–19.47)6.60 (2.67–8.24)< 0.001 (**)11.95 (4.34–24.02)7.13 (3.51–30.43)6.86 (3.51–25.59)0.230.68Eotaxin (pg/mL)172.86 (58.30-409.73)162.23 (65.42-499.65)117.80 (68.78-209.93)0.002 (**)155.46 (66.70-278.65)159.12 (79.40-277.24)153.34 (60.48-340.95)0.940.51FGF (pg/mL)29.92 (19.19–60.92)29.92 (21.36–61.10)25.35 (14.47–41.38)0.02 (**)29.92 (19.19–51.81)34.22 (25.35–46.91)32.35 (21.36–53.03)0.670.98MIP-1 α (pg/mL)2.62 (1.03–8.58)2.16 (0.78–5.23)1.62 (1.03–2.94)0.006 (**)1.89 (1.22–5.58)1.82 (0.91–3.60)1.80 (0.78–4.41)0.050.10T0 - baseline time, T1 - after 3 months, T2 - after 6 months, PUCAI-Pediatric activity index, fCal-fecal calprotectin,, IL-interleukin, FGF- fibroblast growth factor, MIP-1 α- macrophage inflammatory protein 1a.*p < 0.05 for T0 vs. T1, **p < 0.05 for T0 vs. T2, ***p < 0.05 for T1 vs. T2, determined using the Friedman test with post hoc analysis; # results obtained using the Friedman test/Cochran’s Q test with McNemar’s test.## results obtained using the Mann-Whitney U test. Changes in marker levels according to achieved fCal-defined remission assessed by fCal levels at T2. All values are presented as medians with minimum and maximum values. Comparisons within the same groups at T0, T1 and T2 were assessed using the Friedman test with post hoc analysis or cochran’s Q test with mcnemar’s test. Comparisons between groups at T0 were assessed using the Mann-Whitney U test . T0 - baseline time, T1 - after 3 months, T2 - after 6 months, PUCAI-Pediatric activity index, fCal-fecal calprotectin,, IL-interleukin, FGF- fibroblast growth factor, MIP-1 α- macrophage inflammatory protein 1a. *p < 0.05 for T0 vs. T1, **p < 0.05 for T0 vs. T2, ***p < 0.05 for T1 vs. T2, determined using the Friedman test with post hoc analysis; # results obtained using the Friedman test/Cochran’s Q test with McNemar’s test. ## results obtained using the Mann-Whitney U test. Analysis of the usefulness of cytokines in predicting the need for treatment intensification (use of therapy beyond 5-ASA) within 6 months of disease diagnosis in newly diagnosed patients (n = 25) The next step of the study was to analyze the usefulness of cytokines in predicting intensification of therapy. For this purpose, we included only treatment-naïve patients at T0, who were divided according to the treatment used. The division was based on the use of 5-ASA (5-aminosalicylic acid) to induction (5-ASA group) and maintenance of remission vs. the need for other drugs than 5-ASA (5-ASA/IMM group) during 6 months after the diagnosis of UC. The following treatment regimens were used at T1: 5-ASA (n = 19, 76%), 5-ASA + azathioprine (AZA)/ 6-mercaptopurine (6-MP) (n = 4, 16%), 5-ASA + anti-TNFα (n = 1, 4%) and 5-ASA + systemic steroids (n = 1, 4%) and at T2: 5-ASA (n = 17, 68%), 5-ASA + AZA/6-MP (n = 1, 4%), 5-ASA + systemic steroids (n = 1, 4%), 5-ASA + AZA/6-MP/+ cyclosporine (CsA) (n = 1, 4%), 5-ASA + anti-TNFα +/- AZA/6-MP (n = 5, 20%). Throughout the study, 12 (48%) patients were treated with 5-ASA alone. Detailed information on treatment regimens, treatment adjustments and steroid exposure is provided in Table 4 suppl. These variations in therapy, particularly the mandatory use of corticosteroids in the 5-ASA/IMM group, likely influenced both clinical outcomes and cytokine dynamics, emphasizing the exploratory nature of the analyses. In the 5-ASA group, PUCAI, fCal, IL-8, IL-17 and IP-10 decreased significantly, while in the 5-ASA/IMMs group there were changes only in PUCAI and MIP-1 α values over time (Tables 5 and 7 suppl.). Table 7Changes in marker levels according to treatment course: 5-ASA monotherapy vs. treatment intensification within 6 months of diagnosis in ndUC. All values are presented as medians with minimum and maximum values. Comparisons within the same groups at T0, T1 and T2 were assessed using the Friedman test with post hoc analysis. Comparisons between groups at T0 were assessed using the Mann-Whitney U test.Parameters (median; range)5 -ASA group (n = 12, 48.0%)5-ASA/IMMs group (n = 13, 52.0%)T0T1T2P# T0 vs. T1 vs. T2T0T1T2P# T0 vs. T1 vs. T2P## T0 (5-ASA) vs. T0 (5-ASA/IMMs)PUCAI40 (15–75)5 (0–20)5 (0–15)< 0.001 (*, **)65 (10–70)5 (0–80)0 (0–50)0.002 (*, **)0.04fCal (ug/g)2430 (100–3647)101 (20-3602)95 (31-2899)0.02 (*)2726 (358–3975)761 (20-3697)1112 (20-3568)0.230.12IL-6 (pg/mL)3.88 (0.48–29.42)1.35 (0.30–9.58)2.24 (0.48–14.43)0.696.71 (0.30-16.13)4.03 (0.48–27.91)2.96 (0.48–20.47)0.920.02IL-8 (pg/mL)16.77 (1.77–86.15)7.62 (0.98–30.08)7.93 (1.64–23.20)0.02 (*)26.17 (15.43–65.07)18.09 (3.61-100.44)13.00 (4.21–94.40)0.170.01IL-17 (pg/mL)8.77 (3.51–19.47)7.18 (1.83–11.94)5.59 (2.67–7.70)0.04 (**)15.26 (5.18–29.59)8.54 (4.34–30.43)6.86 (2.67–25.59)0.070.03IP-10 (pg/mL)595.70 (142.18-2181.26)341.38 (32.83-915.15)424.50 (133.72-1299.29)0.04 (*)492.87 (274.23-1293.47)511.85 (240.16-971.17)624.41 (134.21-1123.51)0.750.46MIP-1 α (pg/mL)1.97 (1.03–8.58)1.37 (0.78–2.32)1.61 (0.80–4.35)0.072.86 (1.55–5.58)2.22 (1.40–5.23)1.84 (1.19–4.41)0.02 (**)0.07TNFα (pg/mL)42.91 (25.36–80.95)39.83 (20.38–75.49)41.37 (30.25–53.12)0.3656.43 (25.36–81.61)49.77 (39.83–93.55)44.54 (32.67–93.55)0.080.035-ASA- 5-aminosalicylic acid, T0 - baseline time, T1 - after 3 months, T2 - after 6 months, PUCAI-Pediatric activity index, fCal-fecal calprotectin, IL-interleukin, IP-10- interferon gamma-induced protein 10, TNFα-tumor necrosis factor-α, MIP-1 α- macrophage inflammatory protein 1 α,, G-CSF- granulocyte colony stimulating factor, VEGF- vascular endothelial growth factor.*p < 0.05 for T0 vs. T1, **p < 0.05 for T0 vs. T2, ***p < 0.05 for T1 vs. T2, determined using the Friedman test with post hoc analysis; # results obtained using the Friedman test.## Results obtained using the Mann-Whitney U test. Table 7Changes in marker levels according to treatment course: 5-ASA monotherapy vs. treatment intensification within 6 months of diagnosis in ndUC. All values are presented as medians with minimum and maximum values. Comparisons within the same groups at T0, T1 and T2 were assessed using the Friedman test with post hoc analysis. Comparisons between groups at T0 were assessed using the Mann-Whitney U test.Parameters (median; range)5 -ASA group (n = 12, 48.0%)5-ASA/IMMs group (n = 13, 52.0%)T0T1T2P# T0 vs. T1 vs. T2T0T1T2P# T0 vs. T1 vs. T2P## T0 (5-ASA) vs. T0 (5-ASA/IMMs)PUCAI40 (15–75)5 (0–20)5 (0–15)< 0.001 (*, **)65 (10–70)5 (0–80)0 (0–50)0.002 (*, **)0.04fCal (ug/g)2430 (100–3647)101 (20-3602)95 (31-2899)0.02 (*)2726 (358–3975)761 (20-3697)1112 (20-3568)0.230.12IL-6 (pg/mL)3.88 (0.48–29.42)1.35 (0.30–9.58)2.24 (0.48–14.43)0.696.71 (0.30-16.13)4.03 (0.48–27.91)2.96 (0.48–20.47)0.920.02IL-8 (pg/mL)16.77 (1.77–86.15)7.62 (0.98–30.08)7.93 (1.64–23.20)0.02 (*)26.17 (15.43–65.07)18.09 (3.61-100.44)13.00 (4.21–94.40)0.170.01IL-17 (pg/mL)8.77 (3.51–19.47)7.18 (1.83–11.94)5.59 (2.67–7.70)0.04 (**)15.26 (5.18–29.59)8.54 (4.34–30.43)6.86 (2.67–25.59)0.070.03IP-10 (pg/mL)595.70 (142.18-2181.26)341.38 (32.83-915.15)424.50 (133.72-1299.29)0.04 (*)492.87 (274.23-1293.47)511.85 (240.16-971.17)624.41 (134.21-1123.51)0.750.46MIP-1 α (pg/mL)1.97 (1.03–8.58)1.37 (0.78–2.32)1.61 (0.80–4.35)0.072.86 (1.55–5.58)2.22 (1.40–5.23)1.84 (1.19–4.41)0.02 (**)0.07TNFα (pg/mL)42.91 (25.36–80.95)39.83 (20.38–75.49)41.37 (30.25–53.12)0.3656.43 (25.36–81.61)49.77 (39.83–93.55)44.54 (32.67–93.55)0.080.035-ASA- 5-aminosalicylic acid, T0 - baseline time, T1 - after 3 months, T2 - after 6 months, PUCAI-Pediatric activity index, fCal-fecal calprotectin, IL-interleukin, IP-10- interferon gamma-induced protein 10, TNFα-tumor necrosis factor-α, MIP-1 α- macrophage inflammatory protein 1 α,, G-CSF- granulocyte colony stimulating factor, VEGF- vascular endothelial growth factor.*p < 0.05 for T0 vs. T1, **p < 0.05 for T0 vs. T2, ***p < 0.05 for T1 vs. T2, determined using the Friedman test with post hoc analysis; # results obtained using the Friedman test.## Results obtained using the Mann-Whitney U test. Changes in marker levels according to treatment course: 5-ASA monotherapy vs. treatment intensification within 6 months of diagnosis in ndUC. All values are presented as medians with minimum and maximum values. Comparisons within the same groups at T0, T1 and T2 were assessed using the Friedman test with post hoc analysis. Comparisons between groups at T0 were assessed using the Mann-Whitney U test. 5-ASA- 5-aminosalicylic acid, T0 - baseline time, T1 - after 3 months, T2 - after 6 months, PUCAI-Pediatric activity index, fCal-fecal calprotectin, IL-interleukin, IP-10- interferon gamma-induced protein 10, TNFα-tumor necrosis factor-α, MIP-1 α- macrophage inflammatory protein 1 α,, G-CSF- granulocyte colony stimulating factor, VEGF- vascular endothelial growth factor. *p < 0.05 for T0 vs. T1, **p < 0.05 for T0 vs. T2, ***p < 0.05 for T1 vs. T2, determined using the Friedman test with post hoc analysis; # results obtained using the Friedman test. ## Results obtained using the Mann-Whitney U test. Interestingly, comparing the levels of markers measured at T0 significantly higher values of PUCI, IL-6, IL-8, IL-17 and TNFα were found in the 5-ASA/IMMs group. Notably, there was no significant difference in the rate of clinical remission achieved at 6 months post-diagnosis (T2) between the two groups (83% in the 5-ASA group vs. 62% in the 5-ASA/IMM group, p = 0.44). In the 5-ASA group, a significant decrease in IL-17 was observed, suggesting that monitoring cytokine trends may have greater clinical relevance than the initial value alone. ROC analysis The ROC analysis was conducted to determine which markers assessed at T0 had the best predictive value for distinguishing children requiring intensified treatment (Table 8). The best result of AUC (0.801, p = 0.002) was determined for IL-8 with a cut-off value of 20.20 pg/mL and 83.3% sensitivity and 76.9% specificity. Table 8Analysis of diagnostic efficiency of selected markers evaluated at T0 that significantly differentiated patients depending to the treatment regimen used (5-ASA treatment vs. need for intensified treatment within 6 months of disease diagnosis).ParameterAUCSE95% C.I.(AUC) p Cut-offSensitivitySpecificityIL-6 T00.7940.1070.585–0.9990.0065.11 pg/mL81.8%84.6%IL-8 T00.8010.0960.614–0.9890.00220.2 pg/mL83.3%76.9%IL-17 T00.7530.0990.56–0.9460.0110.36 pg/mL66.7%76.9%TNF T00.7600.1030.558–0.9610.0144.54 pg/mL66.7%84.6%PUCAI T00.7500.1120.53–0.970.0345 pts.83.3%76.9%AUC-area under the curve, C.I,-confidence interval, SE-standard error, 5-ASA-5-aminosalicylic acid, IL-interleukin, PUCAI- pediatric activity index, T0- baseline time, pts-points. Table 8Analysis of diagnostic efficiency of selected markers evaluated at T0 that significantly differentiated patients depending to the treatment regimen used (5-ASA treatment vs. need for intensified treatment within 6 months of disease diagnosis).ParameterAUCSE95% C.I.(AUC) p Cut-offSensitivitySpecificityIL-6 T00.7940.1070.585–0.9990.0065.11 pg/mL81.8%84.6%IL-8 T00.8010.0960.614–0.9890.00220.2 pg/mL83.3%76.9%IL-17 T00.7530.0990.56–0.9460.0110.36 pg/mL66.7%76.9%TNF T00.7600.1030.558–0.9610.0144.54 pg/mL66.7%84.6%PUCAI T00.7500.1120.53–0.970.0345 pts.83.3%76.9%AUC-area under the curve, C.I,-confidence interval, SE-standard error, 5-ASA-5-aminosalicylic acid, IL-interleukin, PUCAI- pediatric activity index, T0- baseline time, pts-points. Analysis of diagnostic efficiency of selected markers evaluated at T0 that significantly differentiated patients depending to the treatment regimen used (5-ASA treatment vs. need for intensified treatment within 6 months of disease diagnosis). AUC-area under the curve, C.I,-confidence interval, SE-standard error, 5-ASA-5-aminosalicylic acid, IL-interleukin, PUCAI- pediatric activity index, T0- baseline time, pts-points. Univariate and multivariate analysis Based on univariate logistic regression analysis, two variables assessed at T0, IL-17 and PUCAI were found to be significantly associated with 5-ASA monotherapy. In both cases, lower levels of IL-17 as well as PUCAI at T0 were associated with the use of 5-ASA monotherapy (Table 9). Due to the limited sample size, we refrained from conducting a multivariate logistic regression analysis. Table 9Univariate analysis yielding significant prognostic factors in predicting the need for treatment intensification within 6 months of UC diagnosis.VariableOdds ratio (95% C.I.) p Univariate IL-17 T00.855 (0.739–0.989)0.04PUCAI T00.953 (0.909–0.998)0.04C.I.-confidence interval, IL-interleukin, PUCAI- pediatric activity index, T0 - baseline time. Table 9Univariate analysis yielding significant prognostic factors in predicting the need for treatment intensification within 6 months of UC diagnosis.VariableOdds ratio (95% C.I.) p Univariate IL-17 T00.855 (0.739–0.989)0.04PUCAI T00.953 (0.909–0.998)0.04C.I.-confidence interval, IL-interleukin, PUCAI- pediatric activity index, T0 - baseline time. Univariate analysis yielding significant prognostic factors in predicting the need for treatment intensification within 6 months of UC diagnosis. C.I.-confidence interval, IL-interleukin, PUCAI- pediatric activity index, T0 - baseline time. Discussion In this study, we evaluated changes in serum levels of selected cytokines in children with newly diagnosed or exacerbated UC. We observed different cytokine profiles depending on the achievement of clinical remission and fCal-defined remission. Furthermore, based on our results, we found that in naïvely treated UC patients, some of the cytokines may be useful in predicting the need for intensification of treatment during the first months after diagnosis. To the best of our knowledge, no studies with this design have been conducted to date in either pediatric or adult patients with IBD. As mentioned earlier, most studies evaluating serum cytokines have focused on single-time-point assessments and were primarily conducted in adult patients, without considering the temporal dynamics of cytokine changes. What is more, studies monitoring cytokine levels at different time points mainly refer to therapies that are not routine clinical practice14,15. In our study we observed that IL-8, IL-17, eotaxin and G-CSF had significantly higher levels among UC patients at baseline compared to the control group. At 3 months after treatment inclusion/modification, only IL-17, eotaxin and FGF had still higher concentrations compared to the healthy children. Our observations are consistent with other studies that reported higher levels of serum IL-88 and IL-177,16 in children with UC than in controls. Only one study observed lower IL-17 levels in children with IBD. It should be noted that the group included 42% of children with IBD with unspecified disease duration and treatment regimen, which may have influenced the results17. It should be emphasized that there is a lack of research on the use of IL-17 to predict disease progression in children. In contrast, such studies have been conducted in adults, and IL-17 A measured at the time of diagnosis was shown to predict disease course within three years of diagnosis18. Other biological materials were also used in the research work to assess cytokine concentrations. Higher concentrations of IL-17 were found in coproextracts7 and IL-17 mRNA expression in intestinal mucosa of pediatric patients with IBD compared to controls19,20. Reddy et al. noted elevated levels of IL-8 in the intestinal mucosal lamina propria in IBD, but only in cases with moderate to severe tissue inflammation compared to segments with no inflammation and mild inflammation. However, IL-8 did not differentiate between CD, UC and healthy controls21. In our cohort of pediatric patients with UC, a significant decrease in both IL-8 and IL-17 levels over the six-month follow-up period was observed only in those who achieved clinical remission and showed fCal-defined remission, as indicated by low fCal. Moreover, patients who reached PUCAI < 10 at six months had significantly higher baseline IL-17 concentrations. This was further supported by ROC analysis, which showed a good discriminatory value for IL-17 at baseline. In univariate logistic regression, higher baseline IL-17 levels were significantly associated with a greater likelihood of achieving remission, with each unit increase corresponding to a 26% increase in the odds of clinical remission (OR = 1.26; 95% CI: 1.06–1.50; p = 0.008). However, this association did not remain significant in multivariate analysis, suggesting that the predictive role of IL-17 may depend on other clinical or immunological factors. IL-17 is a pro-inflammatory cytokine that plays a key role in the immune system response. It is mainly produced by Th17 cells and participates in the recruitment of neutrophils and the activation of other immune cells at sites of inflammation22. In autoimmune diseases such as UC, excessive production of IL-17 may contribute to chronic inflammation, tissue damage, and impaired healing of the gastrointestinal mucosa22. In turn, IL-8 plays a key role in the recruitment of neutrophils. In UC, elevated IL-8 levels may exacerbate the inflammatory response6,23. Further long-term studies are needed to investigate the usefulness of IL-17 and IL-8 as non-invasive markers of disease activity in pediatric UC. Literature data regarding the concentrations of specific cytokines, including eotaxin, FGF, RANTES, and G-CSF in children with UC, are notably scarce. A study by Ahrens et al. demonstrated elevated eotaxin-1 mRNA levels in the rectosigmoid colon of pediatric UC patients, as assessed through gene array analysis and quantitative PCR24. The same study, using an animal model, showed that the development of colitis in mice was associated with increased intestinal eotaxin-1 expression and eosinophil recruitment, leading to mucosal damage and aggravated inflammation24. Our study complements these findings by demonstrating that serum eotaxin concentrations at both baseline and after 3 months remained significantly higher in the entire cohort of pediatric UC patients compared to healthy controls. Moreover, baseline eotaxin levels, according to ROC analysis, were able to differentiate between patients who would later achieve clinical remission and those with persistent active disease at 6 months, suggesting its potential role as an early predictive biomarker. Interestingly, no significant changes in eotaxin concentrations were observed between the PUCAI < 10 and PUCAI ≥ 10 subgroups after 6 months of treatment, in contrast to the significant decrease in eotaxin levels noted in children who showed a significant reduction in fCal. This may suggest that this marker reflects inflammatory changes in the intestinal mucosa rather than clinical symptoms. G-CSF was another cytokine whose higher levels were observed in the study group at the time of disease diagnosis and exacerbation. G-CSF plays an important role in regulating the production and function of neutrophils25. In UC, it may contribute to the recruitment and activation of neutrophils at sites of intestinal inflammation, which can lead to further tissue damage, promote the release of proinflammatory mediators, and maintain the chronic inflammation26. To date, only a single study has been published on G-CSF concentrations in children with IBD. Although G-CSF concentrations in UC and CD were comparable, concentrations in patients with relapsing UC were significantly higher than in patients with UC in remission27. In our study, each patient has active UC at the time of enrollment and G-CSF concentrations in this group were significantly higher than in healthy children. However, further studies are needed to better understand the role of G-CSF as a marker of inflammatory activity and disease course in UC. Another cytokine that differentiated the study group from the control was FGF, but only after 3 months of therapy. These changes of FGF may reflect the interplay between intestinal inflammation, tissue remodeling and systemic immune responses. FGF is known to be involved in mucosal healing, angiogenesis, and regulation of epithelial cell proliferation28. At the time of the a publication of article, data on serum FGF levels in children are lacking. Data on adult UC patients are conflicting, both lower and comparable FGF levels were observed between adult UC patients and healthy controls29,30. VEGF was another growth factor whose increase we observed after 6 months in the group of patients with ndUC. This rise may be due to the activation of angiogenesis as part of the inflammatory response characteristic of UC31. No data on serum RANTES concentration in children with IBD have been published so far. In our study, a significant decrease in RANTES levels was observed in the entire study group after three months, followed by an increase to baseline values after six months. Interestingly, such observations were not made in the group of patients with newly diagnosed UC. In addition, elevated RANTES levels were found in patients who exhibited active disease at the 6-month follow-up. Previous studies in adults have shown increased RANTES expression in the colonic mucosa of UC patients and lower plasma levels of RANTES after 5-ASA treatment in IBD patients32–34. In our study, RANTES levels did not differ significantly between patients who required only 5-ASA therapy and those who required treatment intensification. Further studies are needed to clarify the involvement of FGF, RANTES and VEGF in the pathogenesis of UC. Another important finding of our study was that patients requiring only 5-ASA treatment during the first 6 months of the disease had lower baseline IL-6, IL-8, IL-17, and TNFα levels, as well as lower PUCAI scores, at the time of diagnosis. In addition, a significant decrease in IL-8, IL-17, and IP-10 levels was observed only in the group of patients who did not require treatment intensification at 6 months. These findings may suggest the potential usefulness of these markers in predicting the need for treatment escalation during the early course of UC. To the best of our knowledge, the use of selected cytokines for predicting therapeutic outcomes in pediatric UC has not been previously analyzed. However, the predictive value of baseline cytokines cannot be completely separated from the effects of treatment, as patients received different treatment regimens depending on the severity of their disease as determined by clinical assessment. Thus, cytokine associations may partly reflect treatment response rather than intrinsic disease biology. Wang et al. in a group of adult UC patients observed that treatment with 5-ASA showed a significant decrease in IL-17 levels after 4 weeks13. In our study, the group of patients treated with 5-ASA also experienced a decrease in IL-17 levels, which was only noted after 6 months. Among adult patients, the use of cytokines has been mainly concerned with their usefulness in predicting response to biologic therapy or changes in cytokine concentrations under treatment. In a study involving patients with UC, lower IL-6 concentrations were observed at the start of biologic therapy in patients who responded to infliximab after induction treatment35. On the other hand, in another study IL-6 levels before starting anti-TNFα treatment did not further predict the course of treatment, but a decrease in IL-6 levels at week 8 was a predictor of a positive clinical response at week 2636. Bertani et al. evaluated the utility of IL-6 and IL-8 in predicting response to vedolizumab treatment37. They observed that higher IL-8 levels, followed by its significant decrease after 6 weeks of treatment, were associated with achieving fCal-defined remission after one year of treatment. A similar determinant of treatment success was a decrease in IL-6 levels in adult UC patients37. Similarly, higher IL-8 levels before vedolizumab administration, as well as a decrease in IL-6 after 10 weeks of treatment, were predictors of clinical response after one year of vedolizumab treatment12. Furthermore, in a study involving adult patients with both UC and CD, a reduction in IL-6, IL-8, and TNFα levels was observed at week 10 of treatment only in the group that showed a clinical response. However, in a regression model, after taking into account the type of disease, type of biological drug, and disease activity, only a reduction in IL-6 concentration was associated with clinical response after one year38. During our study, anti-TNFα therapy was administered to only 20% of patients with newly diagnosed ulcerative colitis. Due to the limited sample size, statistical analysis in this subgroup was not performed in order to avoid potentially misleading conclusions. The search for prognostic factors in the treatment of ulcerative colitis remains an important and clinically relevant issue. It would be interesting to determine whether, in pediatric patients with IBD, identifying a panel of cytokines can help select individualized therapy. The relationship between baseline cytokine levels, treatment selection and clinical outcomes in pediatric UC is complex. The paradoxical observation that higher concentrations of some pro-inflammatory cytokines (e.g., IL-17, eotaxin, FGF) were associated with a higher likelihood of clinical remission may reflect treatment response dynamics. Patients with more active inflammation at diagnosis might have demonstrated greater relative reductions in cytokine levels under effective therapy, creating the appearance of better outcomes in those with higher baseline values. Treatment decisions were made according to disease severity assessed by clinical and endoscopic criteria, independently of cytokine measurements, which were performed retrospectively. However, cytokine levels, treatment intensity, and outcomes are naturally linked through the degree of inflammation. These findings emphasize that the predictive value of baseline cytokines cannot be fully separated from treatment effects and should be interpreted as exploratory and hypothesis-generating rather than confirmatory. Validation in larger, treatment-controlled pediatric UC cohorts is needed to clarify these associations. This is the first study in pediatric patients with UC to investigate the serum cytokine profile over a six-month observation period. The novelty of these findings is one of the main strengths of our work and may serve as a basis for further research. We also analyzed patients not only in terms of achieving clinical remission but also assessed mucosal healing based on fecal calprotectin levels, as well as the treatment regimens used. This comprehensive approach adds value to our findings. However, our study has potential limitations. Several important limitations should be considered when interpreting our predictive analyses. First, treatment interventions were individualized according to disease severity, introducing a major confounding factor. Patients with more severe disease received intensive therapy (immunomodulators, biologics), whereas those with milder disease received only 5-ASA. Consequently, it is not possible to determine whether baseline cytokine levels reflect the inherent disease prognosis or the response to specific treatments. The observed association between higher baseline IL-17 levels and better outcomes may therefore reflect more aggressive therapy in patients with higher inflammatory markers, rather than a true prognostic relationship. Second, our sample size was too small to perform meaningful multivariate analyses adjusting for treatment intensity. Third, the timing of blood sampling relative to treatment administration, particularly for biologic therapy, may have influenced cytokine measurements at T1 and T2. These exploratory findings require validation in prospective studies with standardized treatment protocols. Such studies should stratify patients by initial treatment regimen or focus on treatment-naïve patients receiving uniform therapy to distinguish prognostic biomarkers from markers of treatment response. Until then, our results should be interpreted as hypothesis-generating rather than clinically actionable. Conclusions In the pediatric population, reliable and non-invasive biomarkers are needed to better identify patients with UC who are at risk of active disease and may require treatment intensification. Our findings indicate that specific serum cytokines exhibit dynamic changes during the treatment of pediatric UC and correlate with established markers of disease activity. Exploratory analyses suggested potential associations between baseline cytokine levels and clinical outcomes; however, these observations require validation in prospective studies with standardized treatment regimens before they can be applied in clinical practice. Methods Patients and study design The prospective study included children with newly diagnosed UC, as well as those with an exacerbation of the disease at the time of study entry. The flow chart illustrating patient inclusion is presented in Fig. 2. We also recruited healthy controls with functional abdominal pain and normal levels of fecal calprotectin, the marker of intestinal inflammation. Participants were recruited between 2020 and 2022. Diagnosis of UC was based on European Society for Pediatric Gastroenterology, Hepatology and Nutrition (ESPGHAN) guidelines, including radiological, endoscopic and histological criteria39. Exclusion criteria for the entire study group included the presence of other autoimmune comorbidities (such as celiac disease, type 1 diabetes, thyroid disorders, and rheumatologic conditions), infectious diseases, as well as parental or patient noncompliance with treatment. None of the patients followed an elimination diet or used dietary supplements or probiotics. To assess disease activity, PUCAI was used and scored as: remission (< 10 points), mild (10–34 points), moderate (35–64 points) or severe (> 64 points)40. Patients were treated according to current recommendations, for mild UC – mesalamine, for moderate UC - mesalamine or systemic steroid if systemic ill, for severe UC – systemic steroid or infliximab if resistant to steroid14,15. Fig. 2Flow chart of patient inclusion and stratification at follow-up (T2). Patients were stratified at 6-month follow-up based on clinical disease activity and fCal-defined remission. Clinical activity was assessed using the Pediatric Ulcerative Colitis Activity Index (PUCAI). Remission was defined as a PUCAI score < 10 and active disease as a PUCAI score ≥ 10. fCal-defined remission was defined as fCal < 250 µg/g, and lack of fCal-defined remission as fCal ≥ 250 µg/g. Flow chart of patient inclusion and stratification at follow-up (T2). Patients were stratified at 6-month follow-up based on clinical disease activity and fCal-defined remission. Clinical activity was assessed using the Pediatric Ulcerative Colitis Activity Index (PUCAI). Remission was defined as a PUCAI score < 10 and active disease as a PUCAI score ≥ 10. fCal-defined remission was defined as fCal < 250 µg/g, and lack of fCal-defined remission as fCal ≥ 250 µg/g. Each patient underwent a colonoscopy at T0. The UC phenotype was assessed using the Paris classification (E1 = proctitis, E2 = colitis distal to the splenic flexure, E3 = extensive distal to the hepatic flexure and E4 = pancolit)41. Endoscopic assessment of UC activity was performed using the Mayo Endoscopic Scale (0 - normal colonic mucosa, 1- erythema, reduced vascular pattern, mild tenderness, 2 - marked erythema, erosions, no vascular pattern, tenderness, 3 - ulceration, spontaneous bleeding)42. For the purpose of the study, three time points of evaluation were chosen: at the time of diagnosis/exacerbation (T0), as well as 3 (T1) and 6 (T2) months after the initiation of treatment. A clinical evaluation of the disease was performed in each patient at T0, T1 and T2. Additionally, after 6 months of treatment (T2), patients with UC were divided into two groups based on PUCAI (remission: <10 points vs. active disease: ≥10 points) and fCal (fCal-defined remission: <250 µg/g vs. no fCal-defined remission: ≥250 µg/g)43. The patients were assessed at time point T2, six months after the initial evaluation, to explore the prognostic significance of the studied markers and their relevance in predicting patient outcomes. To assess the usefulness of the cytokine panel in predicting the need for intensified treatment, only patients with newly diagnosed, treatment-naïve UC were included in the analysis. Patients were divided into the following groups: a group treated with mesalamine alone for induction and maintenance of remission (5-ASA group) and a group requiring additional other treatment (immunomodulators (IMM) like AZA, 6-MMP, CsA, or steroids, biological therapy) within 6 months of UC diagnosis (5-ASA + IMMs). The treatment regimens and medication dosages were consistent with ESPGHAN guidelines14,15. Assessment of fCal and serum inflammatory profile Laboratory tests were performed in each patient at T0, T1 and T2. The blood and stool were collected at the day of admission to hospital. Venous blood was collected via a peripheral venous catheter after an overnight fast. Serum samples were obtained by centrifugation at 4 °C for 15 min at 1000×g. The serum was then frozen at − 80 °C and stored until cytokine panel analysis (described below). The concentration of serum cytokines: IL-1ra, IL-1b, IL-2,IL-4, IL-5, IL-6, IL-7, IL-8, IL-9, IL-10, IL-12, IL-13, IL-15, IL-17, TNF-α, INF- γ, IP-10, MCP-1, MIP-1α, MIP-1β, eotaxin, RANTES, G-CSF, granulocyte-macrophage colony stimulating factor (GM-CSF), VEGF, FGF and PDGF were analyzed in each patient at T0, T1 and T2 using multiplex ELISA method (Bio-Plex Pro Human Cytokine 27-plex Assay; Bio-Rad Laboratories, Inc., Hercules, CA, USA)44. FCal concentration was determined by an enzyme-linked immunosorbent assay (ELISA) kit (IDK Calprotectin; Immundiagnostik, Bensheim, Germany) according to the manufacturer’s instructions. Statistical analysis Statistical tests, calculations and graphics were performed using STATISTICA software. Continuous variables were summarized as median (min-max) and compared using the Mann-Whitney U test; categorical variables were presented as number and percentage and compared using the Chi-square test. Both tests involved comparing patients in groups at the same time point. The Friedman test (continuous variables) and Cochran’s Q test with McNemar’s test (categorical variables) were designed to assess statistical differences within the same groups at T0, T1 and T2. Post hoc analysis was performed using pairwise comparisons with Bonferroni-corrected significance levels. The diagnostic value of marker concentrations was assessed using receiver operating characteristic (ROC) curve analysis. Cutoff values were chosen to calculate the sensitivity, specificity and accuracy of the markers based on the maximization criterion of the J Youden statistic. Spearman’s correlation test was used to analyze correlations between variables assessed at T0 and T2. Univariate and multivariate logistic regression analyses and adjusted odds ratios (ORs) were used to identify factors that contribute to predicting the course of UC. All candidate variables were initially evaluated using univariate logistic regression. Variables that showed statistical significance were then entered into a multivariate logistic regression model. Multivariate logistic regression analysis was performed, adhering to the rule of at least 10 events per variable to ensure model stability. The dependent variable in the regression analyses was clinical remission at 6 months, while baseline cytokine levels served as independent variables. The normality of data distribution was assessed using the Shapiro–Wilk test. Due to the use of nonparametric tests (Mann–Whitney, Friedman), homogeneity of variance was not formally tested. However, during regression analyses (both univariate and multivariate), homoscedasticity was evaluated at the model diagnostics stage and assumptions were met. The significance level was set to p = 0.05. In the statistical analysis, the diagnostic tests used are presented in Fig. 1 suppl. Supplementary Information Below is the link to the electronic supplementary material. Supplementary Material 1 Supplementary Material 1